Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831948 | 0.81 | HIF1A (0.41) | HIF1ASIGMAR1CYP2D6TSHRMEN1 | |
| SCHEMBL11846749 | 0.81 | HIF1A (0.41) | HIF1ASIGMAR1CYP2D6TSHRLMNA | |
| SCHEMBL13494297 | 0.81 | FKBP1A (0.35) | POLBCTDSP1LMNAFKBP1ASMN1; SMN2 | |
| SCHEMBL18872639 | 0.81 | ALDH1A1 (0.37) | TSHRLMNAMAPTALDH1A1 | |
| SCHEMBL12682795 | 0.81 | ALDH1A1 (0.39) | POLBCYP1A2KMT2AALDH1A1HPGD | |
| SCHEMBL596253 | 0.79 | HIF1A (0.39) | HIF1ASIGMAR1CYP2D6APOBEC3AAPOBEC3G | |
| SCHEMBL12014144 | 0.77 | FKBP1A (0.41) | TSHRFKBP1ASMN1; SMN2MAPTKMT2A | |
| SCHEMBL30071020 | 0.77 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL270607 | 0.77 | SIGMAR1 (0.44) | SIGMAR1POLBTSHRLMNASMN1; SMN2 | |
| SCHEMBL6926932 | 0.76 | SIGMAR1 (0.46) | HIF1ASIGMAR1CYP2C9CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258701-A1 | 2-morpholino-4-pyrimidone compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-08 | — | — | EP | claimed |
| CN-121226349-A | Synthesis method of benzomorpholone derivative | 常州大学 | 2025-12-30 | — | — | CN | disclosed |
| CN-118307521-A | Pyrimidine PLK1 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20160096810-A1 | ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-04-07 | — | — | US | disclosed |
| US-20130109572-A1 | HERBICIDAL COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2013-05-02 | — | — | US | disclosed |
| WO-2012006313-A2 | HERBICIDAL COMPOSITIONS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2223916-A1 | Morpholine derivatives as norepinephrine reuptake inhibitors | Eli Lilly and Company (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1682523-B1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7605162-B2 | Indole-3-alkyl-N-piperazine ring substituted with quinoline ring or derivatives; high affinity for both the dopamine D2 receptor and the serotonin reuptake site; nervous system disorders, such as anxiety disorders, depression, Parkinson's disease, and schizophrenia | SOLVAY PHARMACEUTICALS (NL) | 2009-10-20 | — | — | US | disclosed |
| US-20090143406-A1 | New Phenylpiperazine | SOLVAY PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-1534291-A2 | 2-(PHENOXYMETHYL)- AND 2-(PHENYLTHIOMETHYL)- MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005047272-A1 | MORPHOLINE DERIVATIVES AS NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021095-A2 | TREATMENT OF STUTTERING AND OTHER COMMUNICATION DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004103356-A2 | TREATMENT OF EMOTIONAL DYSREGULATION | ELI LILLY AND COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004018441-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004017977-A2 | 2- (PHENOXYMETHYL)- AND 2- (PHENYLTHIOMETHYL)-MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1212320-A2 | PHENYLPIPERAZINES AS SEROTONIN REUPTAKE INHIBITORS | Solvay Pharmaceuticals B.V. (NL) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014330-A2 | PHENYLPIPERAZINES AS SEROTONIN REUPTAKE INHIBITORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143406-A1 | New Phenylpiperazine | HTR5A, HTR2C, HTR3C | HIF1A 1981/4885SIGMAR1 70/4885POLB 4073/4885 |
| US-20130109572-A1 | HERBICIDAL COMPOSITIONS AND METHODS OF USE | DDT, ACHE, CAT | HIF1A 4292/4885SIGMAR1 1976/4885POLB 1406/4885 |
| US-20160096810-A1 | ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ODC1, OSTC, AOC1 | HIF1A 1959/4885SIGMAR1 3472/4885POLB 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.